Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
ATRC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.94 - $43.11
Previous CloseN/A
Volume180.64K
Average Volume (3M)619.67K
Market Cap
$1.70B
Enterprise Value$1.27B
Total Cash (Recent Filing)$122.72M
Total Debt (Recent Filing)$76.53M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Apr 30, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding48,879,604
10 Day Avg. Volume621,175
30 Day Avg. Volume619,675
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.52
Price to Cash Flow (P/CF)70.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.65
Enterprise Value/Ebitda-68.39
Forecast
1Y Price Target
$53.78Price Target Upside59.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Atricure News
PremiumCompany Announcements
AtriCure Highlights Growth and Innovation at Investor Day
PremiumCompany Announcements
AtriCure’s Earnings Call Highlights Strong Growth and Positive Outlook---
Bulls Say, Bears Say
Bulls Say
Financial OutlookAnalyst's price target for AtriCure has been raised from $53 to $57, indicating a strong outlook.
Product DevelopmentThe launch of the Flex Mini device is expanding into new accounts, expected to be a tailwind for several years.
Revenue PerformanceAtriCure announced Q4 revenue of $124.3M, exceeding consensus and forecast expectations.
Bears Say
Growth ExpectationsMIS ablation and MIS appendage management growth are expected to decline in FY25.
Revenue TargetsThe 2028E revenue target was below consensus.
---
Ownership Overview
3.53% Insiders
38.79% Mutual Funds
29.08% Other Institutional Investors
12.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $18.94 and its highest was $43.11 in the past 12 months.
What is Atricure’s market cap?
Atricure’s market cap is $1.70B.
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Apr 30, 2025 which is in 32 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on Feb 12, 2025. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.128.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -0.22.
How many shares outstanding does Atricure have?
Atricure has 48,879,604 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went down -6.539%.
Which hedge fund is a major shareholder of Atricure?
Currently, no hedge funds are holding shares in ATRC
---
Atricure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.78 (59.96% Upside)
$53.78 (59.96% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 100.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.57%
12-Months-Change
Fundamentals
Return on Equity
-9.64%
Trailing 12-Months
Asset Growth
-0.75%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. is a medical device company that develops, manufactures, and sells innovative technologies for the treatment of atrial fibrillation (Afib) and related conditions. The company operates primarily within the healthcare and medical devices sector, offering a range of products and services designed to improve the standard of care for patients with Afib. AtriCure is known for its surgical ablation systems and left atrial appendage management products, which are essential in the treatment of cardiac arrhythmias.
---
ATRC Company Deck
---
ATRC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for AtriCure with significant revenue growth and improved profitability driven by new product launches and international expansion. However, challenges remain in the hybrid AF therapy segment in the U.S. and gross margin declines due to unfavorable mix. The outlook for 2025 is positive, with growth expected to continue, albeit with some pressures in specific segments.Read More>---
ATRC Stock 12 Month Forecast
Average Price Target
$53.78
▲(59.96% Upside)
Technical Analysis
Best Analysts Covering ATRC
1 Year
1 Year Success Rate
19/23 ratings generated profit
1 Year Average Return
+41.86%
reiterated a buy rating 2 days ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 82.61% of your transactions generating a profit, with an average return of +41.86% per trade.
---